Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 744 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mom’s Topless Photo Is Supposed To Encourage Breastfeeding, But Some Think... March 19, 2019 Weekend in New England June 30, 2020 Increased Risk of Cancer in Early Life Among Individuals with Autism... April 28, 2022 ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster... February 4, 2026 Load more HOT NEWS Ending smoking could more than halve England’s cancer inequality gap This Common Antibiotic May Help Support Immune System in Cancer Patients... Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room.
